Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck Mulls Possible Vioxx Reintroduction

Feb 18 2005

• By Lee Kalowski

Related Content

Need For Long-Term CV Studies Goes Beyond COX-2s – Celebrex Study Authors

Feb 15 2005

COX-2 Cardio Risk Is Class Effect, But Varies By Drug And Dose, Cmte. Says

Feb 18 2005

Pfizer Celebrex Polyp Trial Shows Increase In Cardiovascular Events

Dec 17 2004

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window